Hyperfine (HYPR) Net Cash Flow Growth (1y) (2022 - 2026)
Hyperfine (HYPR) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -564.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -31.84% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -394.13% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 57.36% |
| 10 | Hyperfine | 155.82 Mn | 114.55 Mn | 1.98 Mn | 226.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 226.50% |
| Dec 31, 2025 | 268.60% |
| Sep 30, 2025 | 54.66% |
| Jun 30, 2025 | 15.32% |
| Mar 31, 2025 | 67.15% |
| Dec 31, 2024 | 18.26% |
| Sep 30, 2024 | 12.52% |
| Jun 30, 2024 | 4.36% |
| Mar 31, 2024 | 6.69% |
| Dec 31, 2023 | 34.39% |
| Sep 30, 2023 | 31.02% |
| Jun 30, 2023 | 41.73% |
| Mar 31, 2023 | 51.07% |
| Dec 31, 2022 | -112.68% |
| Sep 30, 2022 | -33.13% |
| Jun 30, 2022 | -84.07% |
| Mar 31, 2022 | -217.16% |